BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/29/2024 9:24:50 AM | Browse: 81 | Download: 217
 |
Received |
|
2024-07-31 16:10 |
 |
Peer-Review Started |
|
2024-07-31 16:10 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-09-07 16:11 |
 |
Revised |
|
2024-09-10 20:05 |
 |
Second Decision |
|
2024-09-18 02:47 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-09-18 04:58 |
 |
Articles in Press |
|
2024-09-18 04:58 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2024-09-20 00:48 |
 |
Publish the Manuscript Online |
|
2024-09-29 09:24 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Letter to the Editor |
Article Title |
Anti-tumor efficacy of Calculus bovis: Suppressing liver cancer by targeting tumor-associated macrophages
|
Manuscript Source |
Invited Manuscript |
All Author List |
Ishita Kathuria and Bhupesh Singla |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Institutes of Health grants |
No. K99HL146954 |
National Institutes of Health grants |
No. R00HL146954 |
UTHSC College of Pharmacy Research Seed Grant award |
No. 2023 |
|
Corresponding Author |
Bhupesh Singla, MSc, PhD, Assistant Professor, Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, 881 Madison Ave, Room 446, Memphis, TN 38103, United States. bsingla@uthsc.edu |
Key Words |
Calculus bovis; Liver cancer; M2-like tumor associated macrophages; Wnt/β-catenin pathway; Tumor environment |
Core Tip |
Calculus bovis, a traditional animal drug used in China, has been recognized for its therapeutic effects across various organ systems, including the central nervous, cardiovascular, respiratory, and digestive systems. Recent studies have also suggested its anti-tumor potential. While previous studies have explored the mechanisms of action of its active compounds, this study provides novel insights into its anti-tumor potential using a liver cancer xenograft model. M2 macrophages are associated with tumor progression because they promote tumor growth, angiogenesis, and metastasis while inhibiting effective anti-tumor immune responses. This study, for the first time, demonstrates that Calculus bovis modulates the tumor environment by governing M2-tumor-associated macrophages in a Wnt pathway-dependent manner, thereby suppressing tumor growth. |
Publish Date |
2024-09-29 09:24 |
Citation |
<p>Kathuria I, Singla B. Anti-tumor efficacy of Calculus bovis: Suppressing liver cancer by targeting tumor-associated macrophages. <i>World J Gastroenterol</i> 2024; 30(38): 4249-4253</p> |
URL |
https://www.wjgnet.com/1007-9327/full/v30/i38/4249.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v30.i38.4249 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345